ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio reported a notable 21% increase in net product revenue for Q4 2024, reaching $7.2 million, driven primarily by the accelerating sales of ANKTIVA following its FDA approval. The drug exhibits strong durable response rates, with 51.1% and 48.3% rates at 18 and 24 months, respectively, highlighting its potential for expansion into first-line non-muscle invasive bladder cancer (NMIBC) treatment. Additionally, collaborations, regulatory submissions in Europe, and projected revenue growth from ANKTIVA—expected to reach $137.4 million in 2025 and potentially $4.3 billion by 2034—indicate a robust pathway for future financial performance.

ImmunityBio has experienced operating losses since its inception, with prospects for achieving profitability remaining distant, potentially spanning several years. The company's significant debt and revenue interest liability pose risks to its cash flow and limit its capacity to raise additional capital, which could further complicate its financial stability. Additionally, delays in regulatory approvals and the sluggish uptake of its therapies, particularly in the context of increasing demand for treatments amid rising cancer incidence, contribute to an overall negative sentiment regarding the firm’s stock performance.